- 408.914
- +0.385+0.09%
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
CAMP4 Analyst Highlights Rare Disease Platform Potential
Camp4 Gains After Earning Bullish Views on Street
10 Health Care Stocks Whale Activity In Today's Session
Upstream Shares Are Trading Higher After Multiple Firms Initiated Coverage on the Stock With an Overweight Rating.
12 Information Technology Stocks Moving In Tuesday's Intraday Session
CAMP4 Therapeutics Shares Are Trading Higher After Multiple Firms Initiated Coverage on the Stock With Overweight Ratings.
Wynn Resorts' Q3 Performance Misses Expectations Amid Strategic Investments
Bowhead Specialty Holdings Inc. Non-GAAP EPS of $0.38 Beats by $0.03, Revenue of $116.76M Misses by $0.31M
Webtoon Entertainment Analyst Ratings
Tempus AI Shares Are Trading Lower After the Company Reported Mixed Q3 Financial Results. Also, the Company Announced It Entered Into an Agreement to Acquire Ambry Genetics.
Bitcoin, Ethereum ETFs Record Over $600 Million Net Outflows Ahead Of Election Day
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
William Blair Initiates Coverage On CeriBell With Outperform Rating
CeriBell Analyst Ratings
Broadcom Powers Telia's Modernization With VMware, Launches AI-Driven VeloRAIN & More
Upstream Bio Analyst Ratings
Camp4 Therapeutics Analyst Ratings
Tempus Continues To Expect FY24 Revenue Of ~$700M, Which Represents ~32% YoY Growth And ~$(105M) In Adj EBITDA, An Improvement Of ~$50M Over 2023
Tempus AI Q3 EPS $(0.46) Misses $(0.44) Estimate, Sales $180.93M Beat $179.52M Estimate